Rebecca is a Consultant Medical Oncologist at Guy’s Hospital and an Adjunct Reader in Experimental Therapeutics and Gynaecological Cancer at KCL. She is Research Lead for gynaecological cancer, R&D Lead for Oncology and Clinical Lead for Oncology and Haematology Clinical Trials at Guy’s. She is a Principle Investigator within the Comprehensive Cancer Centre, KCL, a member of the Cancer Early Phase Trials Unit, a Theme Lead within King’s Health Partners ECMC and is Academic Lead for the King’s Health Partners Gynaecological Cancer Biobank.

Rebecca leads development of novel therapeutics for biologically or molecularly selected patients with gynaecological cancer and other solid tumours and has a large portfolio of Phase I-III trials and translational research. She has extensive Phase I-III clinical trial leadership nationally and internationally and has been instrumental in the development and delivery of new licensed drugs in gynaecological cancer, for example rucaparib and dostarlimab. Rebecca enjoys working closely with academic collaborators at KCL and beyond to define and develop innovative treatment approaches for women with gynaecological cancer and welcomes contact from new collaborators.

She is Chief Investigator of the UK academic PEACOCC trial that has set an international benchmark for immunotherapy in clear cell gynaecological cancer and is Global Lead Co-Investigator for the DOVE trial, a follow-on investigator-initiated randomised Phase II trial evaluating immunotherapy combination in the same rare patient group. She lectures, mentors and supervises KCL undergraduate and postgraduate MSc, MD and PhD students and has developed new teaching projects within these course curricula on precision medicine.

Rebecca has published extensively, speaks regularly at international conferences and has held several national and international academic leadership positions in organisations including the British Gynaecological Cancer Society, Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, CRUK New Agents Committee, ESMO and ASCO. Her advice is regularly sought from the pharmaceutical industry.